Antipsychotic-like properties of phosphodiesterase 4 inhibitors: Evaluation of 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (RO-20-1724) with auditory event-related potentials and prepulse inhibition of startle

Journal of Pharmacology and Experimental Therapeutics

Volumn 326, Issue 1, 2008, Pages 230-239

  Halene, T B ^a   Siegel, Steven J ^b  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; AMPHETAMINE; CYCLIC AMP; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; PHOSPHODIESTERASE IV INHIBITOR;

AMPLITUDE MODULATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINE RECEPTOR BLOCKING; DRUG EFFECT; DRUG SCREENING; ENZYME ACTIVITY; EVOKED AUDITORY RESPONSE; LOCOMOTION; MOUSE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; PSYCHOSIS; SENSITIVITY ANALYSIS; SENSORIMOTOR FUNCTION; STARTLE REFLEX;

4-(3-BUTOXY-4-METHOXYBENZYL)-2-IMIDAZOLIDINONE; ACOUSTIC STIMULATION; ANIMALS; ANTIPSYCHOTIC AGENTS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DRUG EVALUATION, PRECLINICAL; EVOKED POTENTIALS, AUDITORY; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; PHOSPHODIESTERASE INHIBITORS; STARTLE REACTION;

EID: 45749156388     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.138586     Document Type: Article

References (41)

1. Cheung YF, Kan Z, Garrett-Engele P, Gall I, Murdoch H, Baillie GS, Camargo LM, Johnson JM, Houslay MD, and Castle JC (2007) PDE4B5, a novel, super-short, brain-specific cAMP phosphodiesterase-4 variant whose isoform-specifying N-terminal region is identical to that of cAMP phosphodiesterase-4D6 (PDE4D6). J Pharmacol Exp Ther 322:600-609.
2. Clapcote SJ, Lipina TV, Millar JK, Mackie S, Christie S, Ogawa F, Lerch JP, Trimble K, Uchiyama M, Sakuraba Y, et al. (2007) Behavioral phenotypes of Disc1 missense mutations in mice. Neuron 54:387-402.
3. Connolly PM, Maxwell CR, Kanes SJ, Abel T, Liang Y, Tokarczyk J, Bilker WB, Turetsky BI, Gur RE, and Siegel SJ (2003) Inhibition of auditory evoked potentials and prepulse inhibition of startle in DBA/2J and DBA/2Hsd inbred mouse substrains. Brain Res 992:85-95.
4. Conti M and Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481-511.
5. Davis JA and Gould TJ (2005) Rolipram attenuates MK-801-induced deficits in latent inhibition. Behav Neurosci 119:595-602.
6. ElvevågB and Goldberg TE (2000) Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 14:1-21.
7. Geyer MA, Krebs-Thomson K, Braff DL, and Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156:117-154.
8. Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC, Woerner MG, Schooler NR, Kane JM, and Robinson DG (2007) Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 64:1115-1122.
9. Gonul AS, Suer C, Coburn K, Ozesmi C, Oguz A, and Yilmaz A (2003) Effects of olanzapine on auditory P300 in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27:173-177.
10. Hill SK, Ragland JD, Gur RC, and Gur RE (2002) Neuropsychological profiles delineate distinct profiles of schizophrenia, an interaction between memory and executive function, and uneven distribution of clinical subtypes. J Clin Exp Neuropsychol 24:765-780.
11. Houslay MD, Schafer P, and Zhang KY (2005) Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 10:1503-1519.
12. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
13. Jin Y, Potkin SG, Patterson JV, Sandman CA, Hetrick WP, and Bunney WE Jr (1997) Effects of P50 temporal variability on sensory gating in schizophrenia. Psychiatry Res 70:71-81.
14. Kane J, Honigfeld G, Singer J, and Meltzer H (1988) Clozapine for the treatmentresistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796.
15. Kanes SJ, Tokarczyk J, Siegel SJ, Bilker W, Abel T, and Kelly MP (2007) Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neuroscience 144:239-246.
16. Kapur S and Mamo D (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27:1081-1090.
17. Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Lewine RR, Yurgelun-Todd DA, Gur RC, Tohen M, et al. (2004) Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 161:985-995.
18. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, et al. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223.
19. Lugnier C (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109:366-398.
20. Maxwell CR, Kanes SJ, Abel T, and Siegel SJ (2004) Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications. Neuroscience 129:101-107.
21. Maxwell CR, Liang Y, Kelly MP, Kanes SJ, Abel T, and Siegel SJ (2006) Mice expressing constitutively active Gsalpha exhibit stimulus encoding deficits similar to those observed in schizophrenia patients. Neuroscience 141:1257-1264.
22. Millar JK, Mackie S, Clapcote SJ, Murdoch H, Pickard BS, Christie S, Muir WJ, Blackwood DH, Roder JC, Houslay MD, et al. (2007) Disrupted in schizophrenia 1 and phosphodiesterase 4B: towards an understanding of psychiatric illness. J Physiol 584:401-405.
23. Mori T, Baba J, Ichimaru Y, and Suzuki T (2000) Effects of rolipram, a selective inhibitor of phosphodiesterase 4, on hyperlocomotion induced by several abused drugs in mice. Jpn J Pharmacol 83:113-118.
24. Murdoch H, Mackie S, Collins DM, Hill EV, Bolger GB, Klussmann E, Porteous DJ, Millar JK, and Houslay MD (2007) Isoform-selective susceptibility of DISC1/phosphodiesterase-4 complexes to dissociation by elevated intracellular cAMP levels. J Neurosci 27:9513-9524.
25. Nakai S, Hirose T, Mori T, Stark A, Araki H, and Kikuchi T (2008) The effect of aripiprazole on prepulse inhibition of the startle response in normal and hyperdopaminergic States in rats. Int J Neurosci 118:39-57.
26. O'Donnell JM and Zhang HT (2004) Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol Sci 25:158-163.
27. Patterson JV, Jin Y, Gierczak M, Hetrick WP, Potkin S, Bunney WE Jr, and Sandman CA (2000) Effects of temporal variability on p50 and the gating ratio in schizophrenia: a frequency domain adaptive filter single-trial analysis. Arch Gen Psychiatry 57:57-64.
28. Ploeger GE, Spruijt BM, and Cools AR (1992) Effects of haloperidol on the acquisition of a spatial learning task. Physiol Behav 52:979-983.
29. Polesskaya OO, Smith RF, and Fryxell KJ (2007) Chronic nicotine doses downregulate PDE4 isoforms that are targets of antidepressants in adolescent female rats. Biol Psychiatry 61:56-64.
30. Rosengarten H and Quartermain D (2002) The effect of chronic treatment with typical and atypical antipsychotics on working memory and jaw movements in three- and eighteen-month-old rats. Prog Neuropsychopharmacol Biol Psychiatry 26:1047-1054.
31. Rummel C, Hamann J, Kissling W, and Leucht S (2003) New generation antipsychotics for first episode schizophrenia. Cochrane Database Syst Rev: CD004410.
32. Rutten K, Lieben C, Smits L, and Blokland A (2007) The PDE4 inhibitor rolipram reverses object memory impairment induced by acute tryptophan depletion in the rat. Psychopharmacology (Berl) 192:275-282.
33. Rutten K, Prickaerts J, and Blokland A (2006) Rolipram reverses scopolamineinduced and time-dependent memory deficits in object recognition by different mechanisms of action. Neurobiol Learn Mem 85:132-138.
34. Scuvée-MoreauJ, Giesbers I, and Dresse A (1987) Effect of rolipram, a phosphodiesterase inhibitor and potential antidepressant, on the firing rate of central monoaminergic neurons in the rat. Arch Int Pharmacodyn Ther 288:43-49.
35. Siegel SJ, Connolly P, Liang Y, Lenox RH, Gur RE, Bilker WB, Kanes SJ, and Turetsky BI (2003) Effects of strain, novelty, and NMDA blockade on auditory-evoked potentials in mice. Neuropsychopharmacology 28:675-682.
36. Siuciak JA, Chapin DS, McCarthy SA, and Martin AN (2007) Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology (Berl) 192:415-424.
37. Swerdlow NR, Geyer MA, Shoemaker JM, Light GA, Braff DL, Stevens KE, Sharp R, Breier M, Neary A, and Auerbach PP (2006) Convergence and divergence in the neurochemical regulation of prepulse inhibition of startle and N40 suppression in rats. Neuropsychopharmacology 31:506-515.
38. Tandon R and Jibson MD (2003) Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 28 (Suppl 1):9-26.
39. Wachtel H (1983) Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors. Neuropharmacology 22:267-272.
40. Zhang HT, Huang Y, Jin SL, Frith SA, Suvarna N, Conti M, and O'Donnell JM (2002) Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology 27:587-595.
41. Zhang KY, Ibrahim PN, Gillette S, and Bollag G (2005) Phosphodiesterase-4 as a potential drug target. Expert Opin Ther Targets 9:1283-1305.